Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Diseases and Conditions Researched
Schizoaffective Disorder; Schizophrenia
What is the purpose of this trial?
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
Click here for detailed participation information for this trial.
|Sponsors:||Stanley Medical Research Institute; Yale University|
|Dates:||December 29, 2007|
|Last Updated:||August 10, 2010|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.